EUVIMEDEUVIMED entdecken
Open Access

Pseudomonas aeruginosa ventricular assist device infections: findings from ineffective phage therapies in five cases

Saima Aslam iD, Dwayne Roach iD, Mikeljon P Nikolich, Biswajit Biswas, Robert T Schooley, Kimberley A Lilly-Bishop iD, Gregory K Rice, Regina Z Cer, Theron Hamilton, Matthew Henry, Tiffany Luong, Ann-Charlott Salabarria und 17 weitere

Antimicrobial Agents and Chemotherapy · 03.04.2024 · 68 (4)

DOI: 10.1128/aac.01728-23 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Antimicrobial Agents and Chemotherapy, erschienen am 03.04.2024. Verfasst von Saima Aslam und 28 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases and Global Public Health and the Center for Innovative Phage Applications and Therapeutics, University of California …. Hauptthemen laut MEDLINE: Phage Therapy, Heart-Assist Devices, Pseudomonas Infections, Bacteriophages. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: University of California Chancellor's Innovation Fund, DOD | USA | MEDCOM | Congressionally Directed Medical Research Programs (CDMRP), DOD | USN | BUMED | Naval Medical Research Command (NMRC).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Left ventricular assist devices (LVAD) are increasingly used for management of heart failure; infection remains a frequent complication. Phage therapy has been successful in a variety of antibiotic refractory infections and is of interest in treating LVAD infections. We performed a retrospective review of four patients that underwent five separate courses of intravenous (IV) phage therapy with concomitant antibiotic for treatment of endovascular Pseudomonas aeruginosa LVAD infection. We assessed phage susceptibility, bacterial strain sequencing, serum neutralization, biofilm activity, and shelf-life of phage preparations. Five treatments of one to four wild-type virulent phage(s) were administered for 14–51 days after informed consent and regulatory approval. There was no successful outcome. Breakthrough bacteremia occurred in four of five treatments. Two patients died from the underlying infection. We noted a variable decline in phage susceptibility following three of five treatments, four of four tested developed serum neutralization, and prophage presence was confirmed in isolates of two tested patients. Two phage preparations showed an initial titer drop. Phage biofilm activity was confirmed in two. Phage susceptibility alone was not predictive of clinical efficacy in P. aeruginosa endovascular LVAD infection. IV phage was associated with serum neutralization in most cases though lack of clinical effect may be multifactorial including presence of multiple bacterial isolates with varying phage susceptibility, presence of prophages, decline in phage titers, and possible lack of biofilm activity. Breakthrough bacteremia occurred frequently (while the organism remained susceptible to administered phage) and is an important safety consideration.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phage TherapyHeart-Assist DevicesPseudomonas InfectionsBacteriophagesBacteremiaHumansPseudomonas aeruginosaAnti-Bacterial AgentsProphages

Stichwörter der Autor:innen

LVADMDROPseudomonas aeruginosadevice-related infectionphage therapy

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • Division of Infectious Diseases and Global Public Health and the Center for Innovative Phage Applications and Therapeutics, University of California San Diego, La Jolla, California, USA.
  • Department of Biology, San Diego State University, San Diego, California, USA.
  • Bacterial Diseases Branch, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
  • Naval Medical Research Command - Frederick, Fort Detrick, Maryland, USA.
  • Leidos, Inc, Reston, Virginia, USA.
  • The Geneva Foundation, Tacoma, Washington, USA.

ORCID-Profile: Saima Aslam, Dwayne Roach, Kimberley A Lilly-Bishop, Andrey A Filippov, Francois Lebreton, Ronen Hazan

Förderung

  • University of California Chancellor's Innovation Fund
  • DOD | USA | MEDCOM | Congressionally Directed Medical Research Programs (CDMRP)
  • DOD | USN | BUMED | Naval Medical Research Command (NMRC)
  • Israeli Science Foundation IPMP
  • Rosetrees Trust (Rosetrees)
  • United States Israel Binational Science Foundation
  • Milgrom Family Support Program

Zitieren

APA

Aslam, S., Roach, D., Nikolich, M. P., Biswas, B., Schooley, R. T., Lilly-Bishop, K. A., Rice, G. K., Cer, R. Z., Hamilton, T., Henry, M., Luong, T., Salabarria, A. C., Sisk-Hackworth, L., Filippov, A. A., Lebreton, F., Hall, L., Nir-Paz, R., Onallah, H., Livni, G., …, & Hazan, R. (2024). Pseudomonas aeruginosa ventricular assist device infections: findings from ineffective phage therapies in five cases. Antimicrobial Agents and Chemotherapy, 68(4). https://doi.org/10.1128/aac.01728-23

Vancouver

Aslam S, Roach D, Nikolich MP, Biswas B, Schooley RT, Lilly-Bishop KA, et al. Pseudomonas aeruginosa ventricular assist device infections: findings from ineffective phage therapies in five cases. Antimicrobial Agents and Chemotherapy. 2024;68(4). doi:10.1128/aac.01728-23

BibTeX
@article{Aslam2024,
  author = {Aslam, Saima and Roach, Dwayne and Nikolich, Mikeljon P and Biswas, Biswajit and Schooley, Robert T and Lilly-Bishop, Kimberley A and Rice, Gregory K and Cer, Regina Z and Hamilton, Theron and Henry, Matthew and Luong, Tiffany and Salabarria, Ann-Charlott and Sisk-Hackworth, Laura and Filippov, Andrey A and Lebreton, Francois and Hall, Lindsey and Nir-Paz, Ran and Onallah, Hadil and Livni, Gilat and Shostak, Eran and Wieder-Finesod, Anat and Yahav, Dafna and Yerushalmy, Ortal and Alkalay-Oren, Sivan and Braunstein, Ron and Khalifa, Leron and Rimon, Amit and Gelman, Daniel and Hazan, Ronen},
  title = {Pseudomonas aeruginosa ventricular assist device infections: findings from ineffective phage therapies in five cases},
  journal = {Antimicrobial Agents and Chemotherapy},
  year = {2024},
  volume = {68},
  number = {4},
  doi = {10.1128/aac.01728-23}
}
Kostenlos starten →